As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

In today’s clinical trials, compared to those of the past, there is increasing complexity, greater data collection, and a ...

Warning that the state’s health care system is “falling apart,” the Senate’s point person on the topic said Thursday that she wants to rein in for-profit and private equity entities as well as give ...

Thermo Fisher is among the industry's best when it comes to cost control. As near-term spending is constrained, the company's margins show exceptional resilience. As of fiscal year-end 2024, Thermo ...

the contribution of emerging markets to the growth of the pharmaceutical market has increased from ... and China to become key nodal points." Analysis of MNCs and companies from emerging countries ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcus Biosciences (RCUS – Research Report), ...

Discover key insights from Pharming Group's Q4 2024 earnings call. Explore strong revenue growth, RUCONEST & Joenja drivers, and 2025 strategic priorities.